About Etrolizumab

Designed to be Gut Selective. Self-Administered.

Learn more about what causes Ulcerative Colitis (UC) and Crohn’s damage in the gut, and lymphocyte trafficking and retention in UC and Crohn’s.

Therapeutic class1-3

Etrolizumab is designed as a dual-action anti-integrin; by specifically targeting the β7 integrin subunit, etrolizumab may inhibit both the α4β7 integrin and the αEβ7 integrin. It is a humanized monoclonal antibody.

How may etrolizumab be different?

Etrolizumab is the first dual-action anti-integrin antibody in Phase III trials designed to selectively control disease in the gut of patients with UC and Crohn’s. By binding the α4β7 integrin, etrolizumab may prevent lymphocytes from binding to MAdCAM-1, thereby potentially inhibiting these cells from entering the gut mucosa. In addition, binding the αEβ7 integrin subunit may prevent lymphocytes from binding to E-cadherin, thereby potentially inhibiting the retention of these cells in the gut mucosa.

During the Etro clinical trials, Etrolizumab can be subcutaneously self-administered every four weeks.

Where is etrolizumab targeted?

Etrolizumab has been designed to target the β7 integrin subunit on gut-selective inflammatory cells. This strategy does not target α4β1.

 

References:
1. Stefanich EG, et al. Br J Pharmacol. 2011;162:1855-70.
2. Rutgeerts PJ, et al. Gut. 2013;62:1122-30.
3. Vermeire S, et al. Lancet. 2014;384:309-18.

  • Print

Notice

×

The information contained in this section of the site is intended for U.S. healthcare professionals only. Please select OK if you are a U.S. healthcare professional.

Cancel OK